Evotec announces agreement with Janssen to develop immune-based therapies

Strategic partnership in oncology

26-Jan-2023 - Evotec SE announced that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration focuses on the development of first-in-class targeted immune-based therapies for ...

Alligator Bioscience to Receive USD 6 Million Milestone Payment from Janssen

08-Jan-2018 - Alligator Bioscience announced that a development milestone payment of USD 6 million has been triggered under the partnership agreement for ADC-1013 (JNJ-64457107) with Janssen Biotech, Inc. The milestone payment is for the partnership agreement to initiate a clinical combination study of ...

MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement

06-Apr-2016 - MorphoSys AG announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. This patent, which is owned by MorphoSys, describes and claims antibodies with particular ...

Genmab achieves USD 45 million milestone

Milestone triggered by first commercial sale of DARZALEX in the United States

23-Nov-2015 - Genmab A/S announced it has achieved a USD 45 million milestone in its DARZALEX™ (daratumumab) collaboration with Janssen Biotech, Inc. The milestone payment was triggered by the first commercial sale of DARZALEX in the United States. "Today marks a significant moment in the history of Genmab - ...

Genmab Reaches USD 10 Million Milestone in Daratumumab Collaboration with Janssen

Milestone triggered by progress in the Phase III study of daratumumab in combination with bortezomib and dexamethasone

28-Oct-2014 - Genmab A/S announced it has reached the fourth milestone in its daratumumab collaboration with Janssen Biotech, Inc.. The USD 10 million milestone payment was triggered by progress in the ongoing Phase III study (“CASTOR” MMY3004) of daratumumab in combination with bortezomib and dexamethasone ...

Phenex and Janssen: Research collaboration for autoimmune and chronic inflammatory disorders

20-Dec-2012 - Phenex Pharmaceuticals AG announced it has entered into an agreement with Janssen Biotech, Inc. and its affiliates to jointly discover compounds that target the nuclear hormone receptor RORγT and may have utility in the treatment of chronic autoimmune and inflammatory disorders including ...

Phylogica licenses technology to Janssen Biotech, Inc.

04-Jan-2012 - Phylogica Ltd announced a Collaboration and Option agreement with Janssen Biotech, Inc., to discover new classes of drugs derived from Phylogica’s Phylomer® peptide platform. In the initial stage of the collaboration, Phylogica will identify cell-penetrating Phylomer® peptides. Under the terms ...

Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc.

13-Dec-2011 - Molecular Partners AG announced that it has entered into a strategic research collaboration and option agreement with Janssen Biotech, Inc. to research, discover and develop DARPin® products for the treatment of immunological diseases. The collaboration and expansion of its current agreement with ...